Recaticimab
drugOn this page
Also known as Shr 1209SHR-1209SHR1209
Summary
Recaticimab (CHEMBL5095381) is a phase-3 clinical-stage antibody targeting PCSK9; indicated across 3 conditions including hyperlipidemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (PCSK9)
- Indications: 3 conditions
- Clinical trials: 14
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095381 |
| Name | Recaticimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Recaticimab, Shr 1209, SHR-1209, SHR1209, RECATICIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| PCSK9 | proprotein convertase subtilisin/kexin type 9 | Binding | 4.6% | Q8NBP7 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): PCSK9.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 1 | PCSK9 |
| VLDLR internalisation and degradation | 1 | PCSK9 |
| Post-translational protein phosphorylation | 1 | PCSK9 |
| LDL clearance | 1 | PCSK9 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| kidney development | 1 |
| liver development | 1 |
| negative regulation of receptor recycling | 1 |
| negative regulation of receptor internalization | 1 |
| positive regulation of receptor internalization | 1 |
| triglyceride metabolic process | 1 |
| phospholipid metabolic process | 1 |
| apoptotic process | 1 |
| lysosomal transport | 1 |
| cholesterol metabolic process | 1 |
| cellular response to starvation | 1 |
| negative regulation of low-density lipoprotein particle clearance | 1 |
| protein autoprocessing | 1 |
| neurogenesis | 1 |
| neuron differentiation | 1 |
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hyperlipidemia | 1 | MONDO:0021187 | MONDO:0021187 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 5 |
| PHASE4 | 3 |
| PHASE2 | 3 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06902740 | PHASE4 | RECRUITING | PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis |
| NCT07290699 | PHASE4 | NOT_YET_RECRUITING | Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period |
| NCT07605130 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial |
| NCT07002476 | PHASE3 | RECRUITING | Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion |
| NCT07119918 | PHASE3 | NOT_YET_RECRUITING | PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis |
| NCT04844125 | PHASE3 | COMPLETED | SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research |
| NCT04849000 | PHASE3 | COMPLETED | Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage |
| NCT04885218 | PHASE3 | COMPLETED | Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia |
| NCT06467617 | PHASE2 | RECRUITING | Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC |
| NCT07062328 | PHASE2 | NOT_YET_RECRUITING | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC |
| NCT03944109 | PHASE1/PHASE2 | COMPLETED | The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia |
| NCT04455581 | PHASE2 | UNKNOWN | A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia |
| NCT03634436 | PHASE1 | COMPLETED | The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects |
| NCT05370950 | PHASE1 | COMPLETED | Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| NILOTINIB | ChEMBL + PubChem | Phase 4 (approved) | PCSK9 |